Proactive - Interviews for investors

Baselode Energy CEO James Sykes joined Steve Darling from Proactive to discuss the company's 2024 exploration plans for its Bear, Catharsis, and Hook uranium projects in northern Saskatchewan's Athabasca Basin. The company is fully financed for what will be the largest exploration programs in its history.

Baselode Energy is planning to conduct 12,000 meters of drilling at the Hook Project, with a focus on delineation and exploration along the strike and depth of the ACKIO mineralized structure. Additionally, the company will deploy "Exosphere By Fleet," an innovative high-resolution ground-based, satellite-connected ambient noise tomography survey.

At the Catharsis Project, the company is planning to drill 8 to 10 holes for 2,000 meters in five different untested target. The drilling program is scheduled to start in mid-February and will run concurrently with a 10,000-line-kilometer high-resolution airborne magnetics and radiometrics survey.

And finally Baselode sys they are planning 6 to 8 drill holes totaling 1,500 meters in 1 to 2 untested target areas on the Bear Project. Drilling is expected to begin in May, then later in the year, a 2,000-line-kilometer gravity and magnetics airborne survey is planned.

Baselode Energy's 2024 exploration plans reflect the company's commitment to advancing its uranium projects and exploring for new mineralization. The Athabasca Basin is known for its high-grade uranium deposits, making it a strategic location for uranium exploration and development.

#proactiveinvestors #baselodeenergycorp #tsxv #find #otcqb #bsenf #mining #uranium

#Exploration2024 #JamesSykesCEO #UraniumDiscoveries #MiningNews #Geophysics #ExosphereTechnology #ResourceExploration #AkeelProject #HookExploration #CatharsisDrilling #BearProject #Mineralization #AmbientNoiseTomography #GroundbreakingTech #MiningIndustry #InvestmentOpportunity #EnergySector #NaturalResources #GeologicalSurvey #MineralExploration #ResourceDevelopment #EconomicGrowth #SustainableEnergy #MiningInvestment

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share significant news regarding the successful completion of the Phase 1a/1b Clinical Trial of NV-CoV-2, targeting the treatment of COVID-19.

Dr. Diwan reported that the healthy subjects participating in the clinical trial have completed their part successfully, with no adverse events reported in any of the multiple ascending dose cohorts. This outcome confirms the excellent safety profile of NV-387, the active ingredient in NV-CoV-2.

All clinical trial subjects were monitored in the hospital during the treatment period, and they have since been discharged. Additionally, they have undergone the final post-discharge follow-up visit, during which no adverse events were reported. Clinical observations during the in-hospital sequestration did not reveal any adverse events, and lab reports on various blood tests, organ function tests, and ECG (heart) tests also showed no adverse events.

NV-387 is designed to target the viral surface and disable the virus's ability to infect cells, similar to how antibiotics such as penicillins attack bacterial surfaces and dismantle bacteria. This ultra-broad-spectrum antiviral activity of NV-387 spans across various virus families, promising revolutionary advancements in the treatment of viral infections and rapid responses to potential pandemics.

NanoViricides' progress in the clinical trial is a significant development in the fight against COVID-19 and other viral infections, potentially paving the way for more effective treatments and pandemic response strategies.

#proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #biotec

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 opened steadily adding 20 to 7,652 with plenty of UK news to digest for investors.

Shop price inflation fell in January to its lowest rate since May 2022 as retailers offered heavy discounts to entice customers.

According to the British Retail Consortium-NielsenIQ, prices were 2.9% higher than a year ago, down from 4.3% in December and below the three-month average of 3.9%.

Johnnie Walker and Guinness owner Diageo slid again as half-year revenue and operating profit fell, reflecting a 23% decline in Latin America & Caribbean sales. Operating profit dropped by 11%.

Retailer Pets At Home also warned about sales, which “fell below its own expectations” in the last three months as discretionary spending slowed. Full-year profit guidance is now around £132 million from £136 million three months ago.

Saga was an early riser as the over 50s specialist said a rebound in travel would mean profits doubling this year.

#ProactiveInvestors #marketreport #Diageo #petsathome #saga #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Eden Research Sean Smith-CEO joined Steve Darling from Proactive to discuss the company's focus on sustainable pesticides for professional agriculture and horticulture. Eden Research is listed on the AIM market and is committed to providing effective, plastic-free pesticides using natural chemistry.

Eden Research's flagship product is a natural fungicide designed to address challenges faced by grape growers globally. This sustainable solution aligns with the growing demand for environmentally friendly crop protection. The company has obtained regulatory approval for sales in the United States, with a particular focus on California, the largest grape producer in the country. This expansion into the US market represents a significant growth opportunity for Eden Research.

Smith told Proactive Eden Research has formed partnerships with industry leaders and is expanding its presence in key countries, including France. The company's global growth strategy aims to provide sustainable pest control solutions to a wide range of agricultural markets.

The interview underscores the importance of sustainability in the agriculture industry and highlights Eden Research's position as a provider of eco-friendly solutions. As the company enters the US market and continues its expansion efforts, 2024 is expected to be a crucial year for Eden Research's commercial success and global market

#proactiveinvestors #edenresearchplc #aim #eden #otcqb #ednsf

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to share significant news regarding the company's decision to terminate its previously announced letter agreement with VCI Global Limited to sell up to a 51% interest in the company's artificial intelligence platform for 3D modeling and associated assets.

Gappelberg explained that the company made the decision to terminate the agreement because VCI Global Limited was unable to meet its conditions precedent within the mutually agreed timelines. As a result, Nextech3D.ai has no plans to sell its 3D modeling business. Instead, the company intends to continue building its AI technology stack to scale 3D modeling while retaining ownership, operation, and development of the business.

The company sees substantial growth potential through partnerships with Amazon and other large enterprise clients, which it believes will provide significant growth opportunities. This strategic decision allows Nextech3D.ai to maintain control over its AI technology and 3D modeling business, positioning it for continued growth and innovation in the industry.

#proactiveinvestors #nextech3d.ai #cse #NTAR #otcqb #metaverse #toggle3D

#3DModeling #TechNews #EcommerceTech #AmazonPartnership #BusinessGrowth #DigitalInnovation #CEOInsights #TechIndustry #EnterpriseDeals #InvestmentUpdate #EmergingTech #FutureTech #DigitalTransformation #EvanGappelberg #VRTechnology #AugmentedReality #DigitalCommerce #InnovationLeadership #TechInnovations #IndustryUpdates #DigitalMarketing #AIIntegration #StrategicPartnerships #AmazonSellerCentral

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

OptionsDesk's Sebastian Blanco previews a busy week on the markets for US corporate earnings and interest-rate decisions.

With five of the "Magnificent Seven" reporting quarterly earnings this week, Blanco highlighted the shift from CPU to GPU chip makers, driven by AI industry demands, noting AMD and Nvidia's emerging leadership. He pointed out Intel's significant revenue forecast miss and Tesla's earnings shortfall last week led to substantial market value losses for both.

Microsoft's recent overtaking of Apple as the world's most valuable company was a significant focus. Blanco attributed Microsoft's success to its dominance in the AI sector, contrasting with Apple's challenges, including softer demand in China and a need to detail its AI strategy. He suggested that Apple's earnings, due on Thursday, would be crucial, especially considering Microsoft's stock surge and Apple's relatively flat performance.

Blanco also shared trading insights, emphasizing the potential of a 'strangle' strategy and the benefits of diversified tech-focused exchange-traded funds (ETFs) in portfolios. He recommended considering ETFs that cover the broader tech sector or those focused on major tech firms, citing the shift towards GPU-focused chipmakers.

‌

#SebastianBlanco #Optionsdesk #TechSector #USearnings #InterestRates #USMarket #UKMarket #TechEarnings #CPUGPUSwitch #AMD #Nvidia #Intel #Tesla #Microsoft #Apple #AIIndustry #StockMarket #TradingStrategies #ETFs #FinancialAnalysis #MarketInsights #Investing #FinanceNews #EconomicTrends #PriceOfLondon #CorporateResults #TechStocks #InvestmentIdeas #FinancialExpert #MarketForecast #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Newmark Security PLC CEO Marie-Claire Dwek takes Proactive's Stephen Gunnion through the company's first-half performance, which revealed strong underlying growth.

The company, which designs and manufactures physical security products, intelligent access control, timekeeping and identity management solutions, reported first-half revenues of £10.4 million and a gross profit of £3.9 million, marking an 11% increase after adjusting for the departure of UKG, a former client.

Notably, EBITDA soared to £5.8 million. The addition of three major clients in the first quarter contributed significantly to revenue. Additionally, Newmark Security has been actively expanding its service offerings, resulting in a notable increase in recurring revenue in HCM, totaling £2.3 million for the year.

Dwek expressed optimism about returning to profit after tax in the second quarter, anticipating a strong second half of the year bolstered by new clients and strategies. The company's focus on attracting more blue-chip customers across various sectors, including software houses in the US and major UK retailers, has been fruitful. Newmark Security's access control division has also seen success with blue-chip clients in the UK through distributors and dealers.

Looking ahead, the sales pipeline remains strong for the second half of the year. Newmark Security's strategic plan, which includes attaching services to hardware and introducing new products to existing partners, is proving successful.

‌

#NewmarkSecurity #MarieClaireDwek #SecurityIndustry #FinancialResults2024 #HCMTimeandAttendance #USMarketExpansion #GrossProfitGrowth #BlueChipClients #RetailSector #AccessControl #EBITDAIncrease #RevenueGrowth #ProactiveInterview #TechInnovation #BusinessStrategy #CorporateGrowth #UKRetailers #SoftwareHouses #ProfitReturn2024 #StrategicPlanning #BusinessInterview #CEOInsights

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Faron Pharmaceuticals Ltd chief executive Dr Markku Jalkanen joined Proactive's Stephen Gunnion with encouraging outcomes from latest cancer treatment trials.

The pharmaceutical company has observed a significant response rate in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Remarkably, within the MDS group, the response rate hit 100%.

These results come from the company's research combining immunotherapy and chemotherapy.

This combination has shown effectiveness even in patients who were previously refractory to standard treatments, including BCL-2 inhibitors, macro Lima, and sundry map. The treatment aims to eradicate cancer cells, leading to complete remission and has demonstrated a profound change in patient profiles.

Dr Jalkanen highlighted that this is part of the second phase of the ongoing 'next map' trial, which involves a careful dose escalation process under FDA guidelines. The trial aims to finalize dosing levels this year, moving towards pivotal phases and regulatory approval.

With a response rate anticipated to be significantly higher than current treatments, the company is eyeing a potential breakthrough in treating aggressive myeloid malignancies, which have short life expectancies.

The company plans to submit additional data from 32 patients to determine the final dose levels, leading to a decisive pivotal trial. With hopes of gaining FDA approval, Faron Pharmaceuticals is positioned to make a substantial impact on cancer treatment, potentially bringing new hope to patients with limited options.

‌

#FaronPharmaceuticals #CancerResearch #Immunotherapy #Chemotherapy #AcuteMyeloidLeukemia #MyelodysplasticSyndromes #ClinicalTrials #MedicalInnovation #FDAApproval #HealthcareNews #Oncology #CancerTreatment #PharmaceuticalIndustry #MedicalBreakthrough #MarkkuJalkanen #CancerTherapy #AML #MDS #NextMapTrial #PharmaNews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Chariot Ltd (AIM:CHAR, OTC:OIGLF) chief executive Adonis Pouroulis says the company is poised for a significant year in 2024, focusing on transitional energy and green initiatives.

In an interview with Proactive's Stephen Gunnion, Pouroulis highlighted key developments across Chariot's diverse portfolio, emphasizing its strategic progress in various sectors.

The primary focus is on Chariot's transitional gas assets, especially in Morocco. The company is set to drill two wells in the Loukos license, with preparations well underway. This move is complemented by a partnership with Energean for offshore Moroccan projects, awaiting regulatory approval. These collaborations aim to expand existing developments and drill a multi-objective appraisal later in the year.

Chariot's trading business in South Africa is addressing the acute energy shortage in the country. The company recently increased its stake to 49% in this venture, foreseeing a significant growth opportunity in one of the world's largest markets undergoing major deregulation.

Renewable projects for mining operations are advancing, with more updates expected. Furthermore, Chariot's green hydrogen pillar is making strides with Project Nour, in partnership with Total Energies in Mauritania. The completed feasibility study will soon be presented to the Mauritanian government.

Despite a recent dip in share price, Pouroulis remains confident in Chariot's solid fundamentals and upcoming catalysts in 2024. The management's significant share ownership and recent purchases by directors affirm their commitment to the company's success.

#ChariotLtd #AdonisPouroulis #EnergySector #TransitionalGas #RenewableEnergy #GreenHydrogen #MoroccoEnergy #EnergeanPartnership #SouthAfricaEnergy #ProjectNora #TotalEnergies #Mauritania #GreenElectricity #EnergyShortage #MiningOperations #EnergyMarket #ShareholderValue #OilAndGasIndustry #EnergyInvestment #CEOInterview #ProactiveLondon #EnergyUpdates2024 #TransitionalEnergy #EnergyInnovation #EnergyStrategy #SustainableEnergy #EnergyDevelopment #GlobalEnergy #EnergyTransition #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Blencowe Resources PLC CEO Mike Ralston joined Proactive's Stephen Gunnion with an update on the company's Orem-Cross Graphite Project after the company received a formal Letter of Interest (LOI) from the US International Development Finance Corporation (DFC) stating the agency is willing to take part in the debt funding for the project.

Ralston told Proactive the project has evolved through various stages, including drilling, scoping studies, and a pre-feasibility study, which indicated an impressive net present value (NPV). Currently, it is in the definitive feasibility study stage. Ralston highlighted graphite's growing importance, especially in lithium-ion batteries, underscoring the high value of the project.

Ralston also elaborated on Blencowe's partnership with DFC. This collaboration began last year with a $5 million grant for feasibility study costs, of which $2 million has already been received. The DFC, committed to funding green projects, aligns with Blencowe's objectives, including critical minerals supply chain development. This partnership is crucial for Blencowe, as DFC will be the lead provider for funding the full project implementation.

Ralston also addressed the EV market and graphite's role in it. While noting a slowdown in the Chinese EV market, he remains optimistic about the overall growth in EVs and lithium-ion batteries. Ralston emphasized graphite's diverse applications beyond EVs and expressed confidence in the Orem-Cross project's potential, given its low capital and operating costs and high-quality product.

#BlencoweResources #MikeRalston #GraphiteMining #OremCrossProject #LithiumIonBatteries #MiningIndustry #ResourceDevelopment #DevelopmentFinanceCorporation #InvestmentInMining #GreenProjects #CriticalMinerals #GraphiteMarket #EVMarket #SustainableMining #LondonStockExchange #BRES #NaturalResources #RenewableEnergy #BatteryMetals #MineralExploration #FeasibilityStudy #CorporateInterview #ProactiveLondon #Finance #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews